Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 16, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Volume | Transaction Type |
|---|---|---|---|---|
| October 13, 2017 | Ordinary Shares (25p each) | £15.1950 | 23 | Acquisition (Dividend Re-investment) |
| October 13, 2017 | Ordinary Shares (25p each) | £15.1950 | 19 | Acquisition (Dividend Re-investment) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine share acquisitions resulting from dividend re-investment plans (DRIP) executed within Individual Savings Accounts (ISAs).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific equity transactions.
Key Facts for Investor Verification
- Transaction Nature: Both reported transactions were acquisitions of ordinary shares via dividend re-investment, not open market purchases.
- Executives Involved: Mr. D S Redfern (Chief Strategy Officer) and Mrs. V A Whyte (Company Secretary).
- Market Price: The shares were acquired at £15.1950 on the London Stock Exchange.
- Volume: The total volume reported in this specific filing is 42 shares (23 + 19).